The company reiterated its revenue guidance forecast of $48 million to $53 million for full-year 2015 and Afirma GEC test volume forecast of 19,000 to 21,000.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The initial CMS pricing for algorithm-based tests has raised objections from labs and industry observers.
The company said its revenues rose on increased sales of its Afirma gene expression classifier tests, which benefited from increased insurance coverage.
The test differentiates benign thyroid nodules from cancerous ones.
The bronchial gene expression classifier test may help prevent lung biopsies by recommending patients for close monitoring instead of surgery.
The increased revenues were driven by a 30 percent uptick in Afirma gene expression classifier test volume.
The new and existing investors will purchase 4,907,975 shares of common stock at $8.15 per share.
The partners will explore the feasibility of combining medical imaging data with genomic and clinical data to inform disease diagnosis.
The firm also disclosed that it has paid $1.2 million in severance and bonuses related to its acquisition of Allegro Diagnostics.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.